Selinexor
Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
What's the purpose of the trial?
The goal of this clinical trial is to learn more about the safety and effectiveness of Selinexor in treating relapsed or refractory multiple myeloma. Researchers seek to accomplish this by comparing two different regimens, selinexor combined with pomalidomide and dexamethasone, and elotuzumab combined with pomalidomide and dexamethasone.
Pomalidomide and dexamethasone are oral drugs that are used to treat relapsed or refractory multiple myeloma. Pomalidomide and dexamethasone in combination with elotuzumab, which is given intravenously, is a standard therapy for relapsed or refractory multiple myeloma. Selinexor is an oral drug, and the all-oral combination of selinexor, pomalidomide, and dexamethasone, where none of the study drugs requires and infusion or injection, is being evaluated in this study and compared to elotuzumab, pomalidomide, and dexamethasone.
Accepting patients
![](https://maps.googleapis.com/maps/api/staticmap?key=AIzaSyDXH19UJTDtS-I9fdYHjFXupEiuQkBgRPk&size=520x280&scale=1&maptype=raodmap&markers=icon%3Ahttps%3A%2F%2Fassets.sparkcures.com%2Fimg%2Fmaps%2Fhospital-default.png%7C32.276699%2C-110.943001%7C36.744202%2C-119.781998%7C33.658162%2C-117.774902%7C34.054212%2C-118.265839%7C34.0909%2C-118.392998%7C33.965784%2C-118.032972%7C40.5718%2C-105.056999%7C26.639999%2C-81.839996%7C27.778299%2C-82.649498%7C30.458552%2C-84.242436%7C26.724889%2C-80.052183%7C21.301045%2C-157.86162%7C42.492562%2C-96.402661%7C30.393447%2C-91.09464%7C39.023998%2C-77.133698%7C40.7724%2C-96.622597%7C39.942001%2C-75.114403%7C35.608042%2C-77.399356%7C40.330367%2C-75.948184%7C32.785286%2C-79.947406%7C34.966824%2C-81.938205%7C30.17234%2C-95.455933%7C33.037156%2C-117.285253%7C30.403958%2C-91.107068%7C35.2122%2C-80.824799%7C36.076%2C-80.296997%7C42.390928%2C-82.914942%7C30.021499%2C-95.438799%7C26.34%2C-80.110001%7C26.0093%2C-80.277603%7C39.468876%2C-119.764816)
Participating Centers
There are 31 centers participating in this trial. Enter a location below to find the closest center.
Experimental Treatments
Learn more about the experimental treatments being evaluated in this clinical trial.
- Dexamethasone is a corticosteroid that prevents the release of substances in the body that cause inflammation, and is given in conjunction with some cancer treatments.
- Elotuzumab is a type of drug called a monoclonal antibody that is used in the treatment of multiple myeloma. Elotuzumab targets a protein called SLAMF7, which is found on multiple myeloma cells.
- Pomalidomide is a kind of medication called an immunomodulatory agent that promotes an immune response to help slow tumor growth. Pomalidomide is used in the treatment of several different indications.
- Selinexor Selinexor is a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor is used in the treatment of multiple myeloma.
Arms / Cohorts
Explore eligibility, treatments and learn more about potential cohorts.
Accepting patients
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.